

November 28, 2023

Songlin Song  
Chief Executive Officer  
Zhengye Biotechnology Holding Limited  
No.1 Lianmeng Road, Jilin Economic & Technical Development Zone  
Jilin City, Jilin Province, China

Biotechnology Holding Limited  
Draft Registration Statement on Form F-1  
17, 2023

Re: Zhengye  
Amendment No. 2 to  
Submitted November  
CIK No. 0001975641

Dear Songlin Song:

We have reviewed your amended draft registration statement and have the following comments.

Please respond to this letter by providing the requested information and either submitting an amended draft registration statement or publicly filing your registration statement on EDGAR. If you do not believe a comment applies to your facts and circumstances or do not believe an amendment is appropriate, please tell us why in your response.

After reviewing the information you provide in response to this letter and your amended draft registration statement or filed registration statement, we may have additional comments.

Amendment No. 2 to Draft Registration Statement on Form F-1  
Use of Proceeds, page 51

1. We note your response to our prior comment 2 and the addition of the "total" row in the table that shows the types of R&D projects the operating entity plans to conduct. Please amend to ensure that the total amounts are properly captured, or otherwise advise. Management's Discussion and Analysis of Financial Condition and Results of Operations Results of Operations Operating expenses, page 65

2. Please describe and quantify research and development costs for individual projects sponsored by the Government of Jilin Province PRC, as discussed on pages 98-103.  
Songlin Song  
FirstName LastNameSonglin Song  
Zhengye Biotechnology Holding Limited  
Comapany 28,  
November NameZhengye  
2023 Biotechnology Holding Limited  
November  
Page 2 28, 2023 Page 2  
FirstName LastName  
Industry  
Analysis of Domestic Top Players' Pet Vaccine Portfolio, page 80

3. We note your response to our prior comment 6 regarding the structure and results of your clinical trials. You state you are currently analyzing the test results and conclusions for project Feline Rhinotracheitis, Feline Rhino conjunctivitis and Feline Panleukopenia TripleInactivated Vaccine. Please revise your disclosure to include a description of the

4. trials that were conducted, including the structure of such trials.  
We note your disclosure that your clinical trials demonstrated that your vaccines associated with batch numbers 2022005 and 2021024 were "safe and effective." Please tell us whether safety and efficacy determinations are solely within the purview of certain Chinese regulatory authorities. If so, please revise your disclosure to remove such claims or advise.  
R&D, page 94

5. We note your disclosure regarding the strategic cooperation framework agreement that the operating entity entered into with Shanghai Veterinary Research Institute, and the subsequently executed Memorandum associated with this agreement. Please revise your disclosure here to note the duration of the agreement as well as the termination provisions of the agreement.

Notes to the Unaudited Condensed Consolidated Financial Statements  
2. Summary of Significant Accounting Policies  
Basis of presentation, page F-32

6. Please provide disclosure required by Rule 3.03(d) of Regulation S-X. Research and development expenses , page F-36

7. Please provide disclosure for your research and development activities as required by ASC 730-20-50, particularly a description and quantification of key terms governing the multiple research projects sponsored by the government of Jilin Province PRC, as discussed on pages 98-103.

8. Intangible Assets, Net, page F-43

8. Please expand your disclosure to describe and quantify the intangible assets licensed under your agreements with Harbin Veterinary Research Institute, China Agricultural University and China Institute of Veterinary Drug Control, as discussed on pages 95-98.

Songlin Song  
FirstName LastNameSonglin Song  
Zhengye Biotechnology Holding Limited  
Comapany 28,  
November NameZhengye  
2023 Biotechnology Holding Limited

November  
Page 3 28, 2023 Page 3  
FirstName LastName

Please contact Franklin Wyman at 202-551-3660 or Daniel Gordon at 202-551-3486 if you have questions regarding comments on the financial statements and related matters. Please contact Doris Stacey Gama at 202-551-3188 or Joshua Gorsky at 202-551-7836 with any other questions.

Sincerely,

Corporation Finance

Division of  
Office of Life

Sciences  
cc: Ying Li, Esq.